{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-139145","form_type":"8-K","ticker":"DCOY","cik":"0001615219","company_name":"Decoy Therapeutics Inc.","filed_at":"2026-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.595033+00:00","generated_at":"2026-05-15T07:50:46.113034+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"confidence":"high","headline":"Decoy Therapeutics regains Nasdaq minimum bid price compliance after reverse split","bullets":["Nasdaq confirmed compliance on March 31, 2026; Common Stock bid price closed at $7.47 on March 20, 2026.","Reverse stock split effective March 6, 2026, to cure bid price deficiency below $1.00.","Company subject to Mandatory Panel Monitor until March 31, 2027; future non-compliance may trigger delisting.","Hearings Panel granted exception until March 20, 2026; compliance achieved with 10 consecutive days above $1.00."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-139145","json":"https://secwatch.observer/filing/0001193125-26-139145.json","markdown":"https://secwatch.observer/filing/0001193125-26-139145.md","text":"https://secwatch.observer/filing/0001193125-26-139145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1615219/000119312526139145/0001193125-26-139145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1615219/000119312526139145/dcoy-20260331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:50:46.113034+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}